SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
View abstract on PubMed
Summary
This summary is machine-generated.SMARCA4 mutations are linked to poor lung cancer prognosis, especially in large cell carcinoma (LCC). Investigating SMARCA4 deficiency via immunohistochemistry is crucial for identifying these aggressive tumors and guiding treatment.
Area Of Science
- Oncology
- Molecular Pathology
Background
- SMARCA4 mutations indicate poor prognosis in lung cancer but lack clear investigation guidelines.
- SWI/SNF complex alterations are implicated in various cancers.
Purpose Of The Study
- To investigate SMARCA4 alterations and their clinicopathological significance in non-small cell lung cancer (NSCLC).
- To determine the prevalence and prognostic value of SMARCA4 aberrations, particularly in large cell carcinoma (LCC).
Main Methods
- Immunohistochemistry (IHC) for SMARCA4 deficiency in 1416 NSCLC patients.
- Comprehensive sequencing of SWI/SNF and SMARCA4 in 397 tumors.
- Multivariable analyses for prognostic factors.
Main Results
- SMARCA4 deficiency found in 2.9% of NSCLC; 9.3% had SMARCA4 mutations.
- SMARCA4 aberrations were significantly higher in LCC (40.5% deficiency, 51.4% mutation).
- SMARCA4 mutation is an independent poor prognostic factor, associated with smoking history and mutually exclusive with EGFR mutations.
Conclusions
- SMARCA4 aberrations, particularly in LCC, hold diagnostic and prognostic value.
- SMARCA4 IHC is essential for identifying aberrant tumors, especially in LCC and those lacking known driver mutations.
- This research highlights the importance of SMARCA4 testing for personalized lung cancer treatment strategies.

